North Carolina Headlines

(Albany, New York)- 10th Sep 2026 – DelveInsight’s latest report, “Pertussis – Market Insight, Epidemiology and Market Forecast – 2036,” provides a comprehensive assessment of the global Pertussis market, covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report evaluates historical and forecasted epidemiology, market dynamics, treatment patterns, vaccination coverage, emerging therapies, competitive intelligence, and future growth opportunities through 2036.

According to DelveInsight, the Pertussis market across the 7MM was approximately USD 4,000 million in 2025 and is projected to reach USD 5,000 million by 2036, expanding at a 2.7% CAGR during 2026–2036. The United States represented the largest market, accounting for nearly USD 3,200 million in 2025.

Key Takeaways from the Pertussis Market

• The 7MM Pertussis market was valued at approximately USD 4,000 million in 2025 and is projected to reach USD 5,000 million by 2036.

• The market is expected to grow at a 2.7% CAGR during 2026–2036.

• The US accounted for approximately 60% of total Pertussis cases across the 7MM in 2025.

• The total Pertussis vaccinated population in the US was approximately 20 million in 2025 and is projected to increase during the forecast period.

• The US Pertussis market was estimated at nearly USD 3,200 million in 2025, making it the largest market among the 7MM.

• Spain accounted for the lowest market share among the 7MM in 2025.

• PENTACEL led the 7MM market in market size due to high-volume pediatric use, while BOOSTRIX demonstrated strong growth potential driven by booster and maternal immunization programs.

• Major marketed vaccines include ADACEL/REPEVAX, BOOSTRIX, HEXAXIM/HEXYON/HEXACIMA, VAXELIS, DAPTACEL, INFANRIX, PEDIARIX, PENTACEL, TETRABIK, TRIBIK/BK1301, QUATTROVAC, TETRAVAC/TETRAXIM, and INFANRIX HEXA.

• Emerging therapies include BPZE1, DPT-IPV-Hib (BK-1310/MT-2355), and DTcP.

Keen to know more about the Pertussis market? Request a sample copy of the report for detailed market insights, epidemiology, treatment patterns, and competitive intelligence.https://www.delveinsight.com/sample-request/pertussis-market

Key Factors Driving the Pertussis Market

Increasing Disease Awareness and Surveillance

Improved diagnosis, surveillance, and reporting systems are contributing to increased detection and recognition of Pertussis cases globally. Greater awareness among healthcare professionals and the public is supporting earlier diagnosis and increasing demand for preventive and therapeutic interventions.

Waning Immunity and Need for Booster Vaccinations

Declining immunity following vaccination is an important factor shaping the Pertussis market. DelveInsight highlights increasing demand for Tdap booster vaccination among adolescents, adults, and pregnant women, particularly as immunity can decline substantially over time.

Expansion of Immunization Programs

Government initiatives and the inclusion of combination vaccines within national immunization schedules are supporting vaccination coverage. Pediatric combination vaccines and maternal immunization programs are expected to remain important contributors to market development during the forecast period.

Resurgence of Pertussis Cases

The resurgence of Pertussis associated with inadequate immunization and waning immunity is creating renewed demand for effective vaccination strategies. The persistence of outbreaks also highlights the need for vaccines capable of providing durable protection and reducing transmission.

Growing Pipeline of Next-generation Vaccines

The development of novel vaccine technologies, including mucosal and intranasal approaches, is expected to create new opportunities. Pipeline candidates such as BPZE1 are being developed with the objective of improving immunity and potentially reducing bacterial colonization and transmission.

Competitive Landscape

The Pertussis market features established pharmaceutical and vaccine manufacturers alongside emerging biotechnology companies developing next-generation vaccines.

Key companies include:

• Sanofi

• GSK

• Biken

• KM Biologics

• ILiAD Biotechnologies

• Mitsubishi Tanabe Pharma Corporation

• Cansino Bio

• Research Foundation for Microbial Diseases of Osaka University, among others.

Established products such as ADACEL/REPEVAX, BOOSTRIX, HEXAXIM/HEXYON/HEXACIMA, and VAXELIS form an important part of the current market, while emerging candidates such as BPZE1, DPT-IPV-Hib, and DTcP could influence the future competitive landscape.

Recent Developments in the Pertussis Market

• February 2026: ILiAD Biotechnologies secured an oversubscribed USD 115 million Series B financing to advance development of its BPZE1 Pertussis vaccine.

• 2025: GSK reported that BOOSTRIX generated USD 122 million in sales in Q3 2025, supporting the company’s established vaccines portfolio.

• June 2024: ILiAD Biotechnologies announced the selection of Emmes Group to conduct upcoming Phase III studies of BPZE1.

• May 2024: ILiAD Biotechnologies reported positive topline interim results for BPZE1 in the SUPER (Stand Up to Pertussis) school-age trial, which included 366 participants across the UK, Australia, and Costa Rica.

• January 2023: The US FDA approved ADACEL for use during pregnancy to help protect newborns against Pertussis.

• October 2022: The US FDA approved BOOSTRIX for maternal immunization to help protect newborns from whooping cough.

• January 2022: The US FDA granted Fast Track designation to BPZE1 for Pertussis booster immunization.

What is Pertussis?

Pertussis, commonly known as whooping cough or the “cough of 100 days,” is an acute and highly contagious respiratory infection caused by Bordetella pertussis. The disease is characterized by prolonged coughing episodes that may be accompanied by an inspiratory “whoop,” posttussive vomiting, and other complications.

Although historically associated with childhood disease, a significant proportion of reported cases now occur among adolescents and adults, partly due to waning immunity following vaccination. Pertussis spreads primarily through respiratory droplets and progresses through catarrhal, paroxysmal, and convalescent stages.

Diagnosis generally involves clinical assessment followed by laboratory confirmation through PCR, culture, or serology, with PCR considered particularly useful during the early stages of infection.

Current Treatment and Prevention Landscape

Treatment depends on the patient’s age and stage of infection. Macrolide antibiotics, including azithromycin and clarithromycin, are the mainstay of treatment, particularly when initiated early. Supportive care is also important, especially for infants and patients with severe disease.

Preventive vaccination remains the most important strategy for reducing Pertussis burden. Childhood DTaP vaccination, adolescent and adult Tdap boosters, and maternal immunization programs play important roles in preventing disease and protecting vulnerable infants.

The current vaccine landscape includes trivalent booster vaccines, pediatric combination vaccines, and hexavalent vaccines. Established products such as ADACEL/REPEVAX and BOOSTRIX support adolescent, adult, and maternal immunization, while products such as HEXAXIM/HEXYON/HEXACIMA and VAXELIS support pediatric vaccination programs.

Pertussis Epidemiology Segmentation

DelveInsight’s epidemiology analysis evaluates the Pertussis patient burden across the 7MM, with particular emphasis on vaccination coverage.

Key epidemiology insights include:

• The US accounted for approximately 60% of total Pertussis cases in the 7MM in 2025.

• Vaccination coverage among children is reported to be high across the 7MM.

• Booster vaccination compliance among adults remains comparatively low.

• The total Pertussis vaccinated population in the US was approximately 20 million in 2025.

• Increasing awareness, updated immunization recommendations, and emerging vaccines are expected to support vaccination coverage during 2026–2036.

• Pertussis can result in serious complications, particularly pneumonia among infants and older adults.

The report’s epidemiological segmentation primarily focuses on total Pertussis vaccination coverage and patient burden assessment.

Scope of the Pertussis Market Report

• Study Period: 2022–2036

• Historical Period: 2022–2025

• Forecast Period: 2026–2036

• Base Year: 2026

• Forecast CAGR: 2.7% (2026–2036)

• Geographies: US, Germany, France, Italy, Spain, UK, and Japan

• Market Size 2025: ~USD 4,000 million

• Projected Market Size 2036: USD 5,000 million

• Epidemiology Segmentation: Total Pertussis vaccination coverage and patient burden assessment

• Market Segmentation: Region/geographies and drugs/therapies

• Key Analysis: KOL views, SWOT analysis, reimbursement, conjoint analysis, unmet needs, market drivers and barriers, and epidemiological patient burden

• Key Strengths: Epi-based bottom-up forecasting, AI-enabled market research, 11-year forecast, regional market outlook, patient burden trends, treatment addressable market, competitive landscape, company insights, price trends and analogue assessment, therapy adoption/uptake, and peak patient share analysis.

To know more about the Pertussis Market Report Pertussis Market Insight, Epidemiology and Market Forecast – 2036

Table of Contents

1. Report Introduction

2. Pertussis Executive Summary

3. Pertussis Disease Overview

4. Epidemiology and Patient Burden

5. Pertussis Diagnosis and Treatment Algorithm

6. Current Treatment Landscape

7. Pertussis Marketed Therapies

8. Pertussis Emerging Therapies and Pipeline Analysis

9. Competitive Landscape

10. Pertussis Market Size and Forecast

11. Market Drivers and Barriers

12. Unmet Medical Needs

13. Market Access and Reimbursement

14. Pricing and Analogue Assessment

15. KOL and Expert Insights

16. SWOT and Conjoint Analysis

17. Regional Market Analysis

18. Company and Therapy Profiles

19. Market Outlook and Future Opportunities

20. Conclusions and Strategic Insights

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/